1Holman R R.The Treat-to-Target Trial:randomized addition of glargine or human NPH to oral therapy of type 2 diabetes[J].Diabetes Res Clin Pract,1998,40(suppl 1):S21-S25.
2Creutzfeldt W.The entero-insular axis in type 2 diabetes-incretins as therapeutic agents[J].Exp Clin Endocrinol Diabetes,2001,109(Suppl 2):S288-S303.
3Blonde L,Klein E J,Han J,et al.Interim analysis of the effects of exenatide treatment on AIC,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes Obes Metab,2006,8:436-447.
4Kendall DM,Riddle MC,Rosenstock J,et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J].Diabetes Care,2005,28(5):1083-1091.
5Raz I,Chen Y,Wu M,et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[J].Carr Med Res Opin,2008,24(2):537-550.
6Nonaka K,Kakikawa T,Sato A,et al.Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes[J].Diabetes Res Clin Pract,2008,79(2):291-298.
7Hermansen K,Kipnes M,Luo E,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepitide and metformin[J].Diabetes Obes Metab,2007,9(5):733-745.
8DeFronzo RA,Okerson T,Viswanathan P,et al.Effects of exeuatide versus sitagliptin on postprandial glucose,insulin and glueagon secretion,gastric emptying,and caloric intake:a randomized,oross-over study[J].Curr Med Res Opin,2008,24(10):2943-2952.
9Raz L,Chen Y,Wu M,et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[J].Curr Med Res Opin,2008,24(2):537-550.
